Financial Summary
Aptevo Therapeutics Inc. (APVO)
Healthcare
★
★
★
★
Buy
A-
| Symbol | APVO |
|---|---|
| Price | 0.636$ |
| Beta | 2.51 |
| Volume Avrg. | 0.37M |
| Market Cap | 0.03B |
| Shares (2018) | 22,500.05K |
| Last Div | 0 |
| Dividend Yield | - |
| DCF Unlevered | - | |
|---|---|---|
| DCF Levered | - | |
| ROE | -176.57% | Strong Sell |
| ROA | -147.98% | Strong Sell |
| Operating Margin | -223.98% | Strong Sell |
| Debt / Equity | 63.40% | Buy |
| P/E | - | Neutral |
| P/B | 0.95 | Buy |
Income Statement
| Year | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|
| Earnings Per Share Basic | - | - | -2.93 | -5.55 | 0.33 | -2.39 |
| Net Profit Margin | -313.75 | -1.12 | -1.77 | -3.09 | 0.48 | -2.33 |
| Earnings Per Share Diluted | - | - | -2.93 | -5.55 | 0.33 | -2.39 |
| Revenue | 0.17 | 45.63 | 33.60 | 36.43 | 14.66 | 23.07 |
| Weighted Average Shares Outstanding | - | - | 20.21 | 20.24 | 21.34 | 22.50 |
| Gross Profit | 0.17 | 29.38 | 16.67 | 12.25 | 9.65 | 11.85 |
| Weighted Average Shares Outstanding (Diluted) | - | - | 20.23 | 20.24 | 21.34 | 22.50 |
| Sales, General and Administrative Expense | 15.45 | 34.28 | 43.04 | 77.33 | 69.15 | 56.27 |
| Dividend per Share | - | - | - | - | - | - |
| Operating Income | -53.34 | -51.71 | -61.10 | -126.94 | -53.95 | -51.66 |
| Gross Margin | 1.00 | 0.64 | 0.50 | 0.34 | 0.66 | 0.51 |
| Earnings before Tax | -53.34 | -51.71 | -61.34 | -127.75 | -16.33 | -53.69 |
| EBITDA Margin | -309.83 | -1.09 | -1.74 | -3.39 | -3.47 | -2.14 |
| Net Income | -53.34 | -51.12 | -59.32 | -112.42 | 6.97 | -53.69 |
| EBIT Margin | -313.75 | -1.13 | -1.83 | -3.48 | -3.68 | -2.24 |
| Net Income - Discounted ops | - | - | - | - | - | - |
| Profit Margin | -313.75 | -1.12 | -1.76 | -3.09 | 0.48 | -2.33 |
| Preferred Dividends | - | - | - | - | - | - |
| Free Cash Flow margin | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| R&D Expenses | 38.07 | 46.59 | 34.73 | 29.52 | 29.02 | 35.38 |
| Interest Expense | - | - | - | -15.34 | -23.30 | - |
| Earnings Before Tax Margin | -313.75 | -1.13 | -1.83 | -3.51 | -1.11 | -2.33 |
| Consolidated Income | -53.34 | -51.12 | -59.32 | -112.42 | 6.97 | -53.69 |
| EBIT | -53.34 | -51.71 | -61.34 | -126.94 | -53.95 | -51.66 |
| EBITDA | -52.67 | -49.69 | -58.43 | -123.58 | -50.82 | -49.27 |
| Income Tax Expense | - | -0.60 | -2.02 | -15.34 | -23.30 | - |
| Operating Expenses | 53.51 | 81.09 | 77.77 | 106.85 | 98.17 | 91.65 |
| Cost of Revenue | - | 16.25 | 16.93 | 24.18 | 5.01 | 11.21 |
| Net Income Com | -53.34 | -51.12 | -59.32 | -112.42 | 6.97 | -53.69 |
| Net Income - Non-Controlling int | - | - | - | - | - | - |
Balance Sheet Statement
| Year | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Total current liabilities | 19.84 | 19.94 | 19.54 | 18.51 | 17.61 |
| Other Liabilities | 8.36 | 9.86 | - | - | - |
| Long-term debt | - | - | 18.38 | 15.73 | 19.28 |
| Cash and cash equivalents | 3.59 | 4.64 | 9.68 | 7.09 | 30.64 |
| Total debt | - | - | 18.38 | 19.06 | 20.07 |
| Cash and short-term investments | 3.59 | 4.64 | 9.68 | 7.09 | 30.74 |
| Deferred revenue | 4.54 | 7.16 | 0.81 | - | - |
| Inventories | 17.63 | 20.32 | 6.64 | 1.03 | 1.78 |
| Tax Liabilities | 1.87 | 15.82 | - | - | - |
| Goodwill and Intangible Assets | 25.12 | 46.65 | - | 6.08 | 5.25 |
| Deposit Liabilities | - | - | - | - | - |
| Tax assets | 1.31 | 1.38 | - | - | - |
| Total non-current liabilities | 5.53 | 19.21 | 21.75 | 16.46 | 19.48 |
| Total current assets | 41.55 | 35.13 | 71.41 | 95.08 | 48.69 |
| Total liabilities | 25.36 | 39.15 | 41.29 | 34.97 | 37.09 |
| Payables | 11.47 | 10.08 | 11.49 | 7.35 | 11.67 |
| Other comprehensive income | - | - | 131.27 | 155.84 | 157.79 |
| Short-term investments | - | - | - | 78.11 | 0.10 |
| Retained earnings (deficit) | -172.67 | -231.99 | -80.69 | -73.72 | -127.41 |
| Property, Plant & Equipment Net | 3.20 | 4.18 | 5.91 | 5.84 | 5.20 |
| Total non-current assets | 78.42 | 92.63 | 20.44 | 21.92 | 18.80 |
| Other Assets | 6.51 | 3.72 | - | - | - |
| Net Debt | -3.59 | -4.64 | 8.71 | 11.97 | -10.56 |
| Investments | - | - | - | 78.11 | 0.10 |
| Total shareholders equity | 94.61 | 88.62 | 50.57 | 82.03 | 30.41 |
| Total assets | 119.97 | 127.77 | 91.86 | 117.01 | 67.49 |
| Long-term investments | - | - | - | - | - |
| Receivables | 13.82 | 6.46 | 4.28 | 2.14 | 5.22 |
| Short-term debt | - | - | - | 3.33 | 0.80 |
Cash Flow Statement
| Year | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|
| Insurance (repayment) of debt | - | - | - | - | - | - |
| Net Cash/Marketcap | 0.00 | 0.00 | 0.00 | - | - | - |
| Insurance (buybacks) of shares | - | - | - | - | - | - |
| Depreciation & Amortization | 0.67 | 2.02 | 2.91 | 3.36 | 3.13 | 2.39 |
| Dividend payments | - | - | - | - | - | - |
| Operating Cash Flow | -51.39 | -47.01 | -48.76 | -36.86 | -41.57 | -51.42 |
| Acquisitions and disposals | - | -47.81 | - | - | - | - |
| Free Cash Flow | -52.41 | -48.00 | -50.29 | -39.37 | -42.98 | -52.40 |
| Net cash flow / Change in cash | - | 3.59 | 1.04 | 5.04 | -2.58 | 20.59 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Financing Cash Flow | 52.41 | 99.40 | 51.33 | 89.30 | 9.53 | -0.79 |
| Investment purchases and sales | - | - | - | - | - | - |
| Capital Expenditure | -1.02 | -0.99 | -1.53 | 2.51 | 1.40 | 0.98 |
| Stock-based compensation | 0.95 | 1.07 | 1.11 | 3.81 | 4.88 | 2.14 |
| Investing Cash Flow | - | - | - | - | - | - |
Retained Earning Schedule
| Year | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Retained Earnings (Previous Year) | - | -173 | -232 | -81 | -74 |
| Net Income | -51 | -59 | -112 | 7 | -54 |
| Stock Dividends | -122 | - | 264 | - | - |
| Divident Paid | - | - | - | - | - |
| Retained Earnings | -173 | -232 | -81 | -74 | -127 |
PPE Schedule
| Year | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Year | 2014 | 2015 | 2016 | 2017 | 2018 |
| Gross PPE | - | 3 | 4 | 6 | 6 |
| Annual Depreciation | 4 | 3 | -1 | -1 | -2 |
| Capital Expenditure | -1 | -2 | 3 | 1 | 1 |
| Net PPE | 3 | 4 | 6 | 6 | 5 |
Intangible and Goodwill Schedule
| Year | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Intangible and Goodwill (Previous Year) | - | 25 | 47 | - | 6 |
| New Purchases | - | - | - | - | - |
| Intangible and Goodwill | 25 | 47 | - | 6 | 5 |
Aptevo Therapeutics Inc. (APVO)
0.636
-0.024 (-3.64%)
About
Aptevo Therapeutics Inc is a biosciences company. The Company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.